AllianceBernstein’s Genmab GMAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$294M Sell
9,557,149
-1,319,945
-12% -$39.6M 0.1% 164
2025
Q4
$335M Sell
10,877,094
-76,819
-0.7% -$2.39M 0.11% 152
2025
Q3
$336M Buy
10,953,913
+291,538
+3% +$7.1M 0.11% 152
2025
Q2
$220M Sell
10,662,375
-4,062,783
-28% -$83.4M 0.07% 204
2025
Q1
$288M Sell
14,725,158
-210,066
-1% -$4.41M 0.1% 165
2024
Q4
$312M Sell
14,935,224
-200,928
-1% -$4.41M 0.11% 149
2024
Q3
$369M Sell
15,136,152
-101,687
-0.7% -$2.72M 0.12% 136
2024
Q2
$383M Sell
15,237,839
-16,508
-0.1% -$468K 0.13% 133
2024
Q1
$456M Sell
15,254,347
-360,163
-2% -$10.6M 0.16% 122
2023
Q4
$497M Buy
15,614,510
+6,099,301
+64% +$192M 0.19% 101
2023
Q3
$336M Buy
9,515,209
+1,327,633
+16% +$50.6M 0.14% 134
2023
Q2
$311M Buy
8,187,576
+1,420,915
+21% +$56.7M 0.13% 150
2023
Q1
$256M Buy
6,766,661
+431,043
+7% +$16.6M 0.11% 163
2022
Q4
$269M Buy
6,335,618
+556,129
+10% +$22.9M 0.12% 159
2022
Q3
$186M Buy
+5,779,489
New +$203M 0.09% 201
2021
Q4
Sell
-133,868
Closed -$5.85M 3314
2021
Q3
$5.85M Buy
133,868
+7,628
+6% +$342K ﹤0.01% 1524
2021
Q2
$5.15M Buy
+126,240
New +$4.87M ﹤0.01% 1594
2020
Q4
Sell
-309,209
Closed -$11.3M 3177
2020
Q3
$11.3M Buy
309,209
+115,218
+59% +$4.17M 0.01% 990
2020
Q2
$6.57M Buy
+193,991
New +$5.29M ﹤0.01% 1188

Other funds holding GMAB

AllianceBernstein's GMAB Position: Q1 2026 in Review

AllianceBernstein reduced its Genmab (GMAB) stake by 12% in Q1 2026, selling an estimated $39.6M and leaving 9,557,149 shares worth $294M. The position accounts for 0.1% of the portfolio, ranked #164.

AllianceBernstein first reported a position in GMAB in Q2 2020 and has held it in 19 quarters since. The position peaked at $497M in Q4 2023. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • AllianceBernstein held 9,557,149 shares of Genmab worth $294M as of Q1 2026.
  • AllianceBernstein sold 1,319,945 Genmab shares in Q1 2026, an estimated $39.6M.
  • Genmab made up 0.1% of AllianceBernstein's portfolio in Q1 2026, its #164 holding.
  • AllianceBernstein first reported a position in Genmab in Q2 2020 and has held it in 19 quarters since.
  • AllianceBernstein's Genmab position peaked at $497M in Q4 2023.
  • 272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.